ABOUT
HemoGenyx is a biopharmaceutical company developing a new treatment for blood diseases, such as leukemia, lymphoma and bone marrow (“BM”) failure. The Company leverages a special class of cells that can generate cancer-free, patient-matched blood stem cells. These cancer-free cells can then be used in BM and blood (hematopoietic) stem cell (“HSC”) transplants, which will improve the efficacy of BM/HSC transplants and make BM/HSC transplants a viable treatment option for many patients that wouldn’t otherwise be able to find a matching donor.
WATCH
CEO
Co-founder and CEO